Pathways to Precision: Guideline for Programmed Death Ligand-1 and Tumor Mutation Burden Testing to Support the Selection of Immune Checkpoint Therapies in Lung Cancer-Reference-Cited by-同舟云学术

Pathways to Precision: Guideline for Programmed Death Ligand-1 and Tumor Mutation Burden Testing to Support the Selection of Immune Checkpoint Therapies in Lung Cancer

Published:2024-06-25 Issue:7 Volume:148 Page:754-756
ISSN:1543-2165
Container-title:Archives of Pathology & Laboratory Medicine
language:en
Short-container-title:

Author:

Cecchini Matthew J.¹

Affiliation:

1. From the Department of Pathology and Laboratory Medicine, London Health Sciences Centre, University Hospital, London, Ontario, Canada

Publisher

Archives of Pathology and Laboratory Medicine

Link

https://meridian.allenpress.com/aplm/article-pdf/148/7/754/3391671/i1543-2165-148-7-754.pdf

Reference26 articles.

1. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50;Reck;J Clin Oncol,2021

2. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial;Mok;Lancet,2019

3. Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial;Jotte;J Thorac Oncol,2020

4. Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 trial;Nishio;J Thorac Oncol,2021

5. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 tria;West;Lancet Oncol,2019